
    
      The purpose of this trial is to test if VC-02â„¢ combination product can be implanted
      subcutaneously in subjects with Type 1 Diabetes and Hypoglycemia Unawareness and maintained
      safely for up to two years. It will also test if VC-02 is an effective treatment for these
      subjects.
    
  